Home Cart Sign in  
Chemical Structure| 392721-37-8 Chemical Structure| 392721-37-8

Structure of Fasentin
CAS No.: 392721-37-8

Chemical Structure| 392721-37-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Fasentin is a GLUT1 and GLUT4 inhibitor (IC50 = 68 μM). Preferentially inhibits GLUT4 over GLUT1.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Fasentin

CAS No. :392721-37-8
Formula : C11H9ClF3NO2
M.W : 279.64
SMILES Code : CC(CC(NC1=CC=C(Cl)C(C(F)(F)F)=C1)=O)=O
MDL No. :MFCD01001285
InChI Key :GNYIJZMBLZXJEJ-UHFFFAOYSA-N
Pubchem ID :879520

Safety of Fasentin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Peripheral blood mononuclear cells (PBMCs) 25 μM 6 hours Inhibition of GLUT-1-mediated glucose internalization, reduction of PKM2 nuclear translocation, and down-regulation of pro-inflammatory cytokine expression Cardiovasc Res. 2023 Dec 19;119(16):2653-2662
A549 cells 10 μM 24 hours To investigate the effect of Fasentin on Nrf2 protein expression, results showed that Fasentin significantly increased the expression level of Nrf2 protein. Int J Mol Sci. 2021 Jun 19;22(12):6582
A549 cells 10 μM 6 hours To investigate the effect of Fasentin on the expression of glucose transporters and metabolic enzymes, results showed that Fasentin increased the expression levels of these proteins. Int J Mol Sci. 2021 Jun 19;22(12):6582
GSC28 cells 50 µM 24 hours Inhibits GLUT1 expression but does not alter TUBB4 expression Cancers (Basel). 2019 Sep 5;11(9):1308
GSC33 cells 50 µM 24 hours Inhibits GLUT1 expression but does not alter TUBB4 expression Cancers (Basel). 2019 Sep 5;11(9):1308
GLC-36 50.0 and 100.0 µM 4 days analyze cell proliferation and survival, significant negative impact on cell numbers at high concentrations Cancers (Basel). 2023 Feb 23;15(5):1415
GLC-2 50.0 and 100.0 µM 4 days analyze cell proliferation and survival, significant negative impact on cell numbers at high concentrations Cancers (Basel). 2023 Feb 23;15(5):1415
QPG-1 50.0 and 100.0 µM 4 days analyze cell proliferation and survival, significant negative impact on cell numbers at high concentrations Cancers (Basel). 2023 Feb 23;15(5):1415
BON-1 50.0 and 100.0 µM 4 days analyze cell proliferation and survival, significant negative impact on cell numbers at high concentrations Cancers (Basel). 2023 Feb 23;15(5):1415
human gingival fibroblasts (HGF) 25, 50, 100 µM 72 hours To evaluate the effect of Fasentin on cell proliferation, results showed that Fasentin inhibited HGF proliferation with an IC50 of 111.2 ± 27.0 µM. Sci Rep. 2020 Apr 9;10(1):6132
human cervix adenocarcinoma cells (HeLa) 25, 50, 100 µM 72 hours To evaluate the effect of Fasentin on cell proliferation, results showed that Fasentin inhibited HeLa proliferation with an IC50 of 31.9 ± 1.4 µM. Sci Rep. 2020 Apr 9;10(1):6132
human breast carcinoma cells (MCF7) 25, 50, 100 µM 72 hours To evaluate the effect of Fasentin on cell proliferation, results showed that Fasentin inhibited MCF7 proliferation with an IC50 of 34.7 ± 4.0 µM. Sci Rep. 2020 Apr 9;10(1):6132
human breast carcinoma cells (MDA-MB-231) 25, 50, 100 µM 72 hours To evaluate the effect of Fasentin on cell proliferation, results showed that Fasentin inhibited MDA-MB-231 proliferation with an IC50 of 26.3 ± 4.8 µM. Sci Rep. 2020 Apr 9;10(1):6132
bovine aortic endothelial cells (BAEC) 25, 50, 100 µM 72 hours To evaluate the effect of Fasentin on cell proliferation, results showed that Fasentin inhibited BAEC proliferation with an IC50 of 42.7 ± 9.5 µM. Sci Rep. 2020 Apr 9;10(1):6132
human umbilical vein endothelial cells (HUVEC) 25, 50, 100 µM 72 hours To evaluate the effect of Fasentin on cell proliferation, results showed that Fasentin inhibited HUVEC proliferation with an IC50 of 27.6 ± 3.7 µM. Sci Rep. 2020 Apr 9;10(1):6132
human microvascular endothelial cells (HMEC) 25, 50, 100 µM 72 hours To evaluate the effect of Fasentin on cell proliferation, results showed that Fasentin inhibited HMEC proliferation with an IC50 of 27.9 ± 14.5 µM. Sci Rep. 2020 Apr 9;10(1):6132
AtT-20/D16:16 cells 1 μM and 40 μM 3 hours Fasentin inhibited baseline and CRH-mediated glucose uptake Mol Cell Endocrinol. 2018 Jul 15;470:105-114
human cardiac progenitor cells (hCPCs) 1 μM 72 hours Fasentin restored hCPC viability and tube-forming ability by specifically inhibiting GLUT1 and reduced the expression of mitochondrial fission-related proteins Fis1 and Drp1. Biomol Ther (Seoul). 2016 Jul 1;24(4):363-70

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.58mL

0.72mL

0.36mL

17.88mL

3.58mL

1.79mL

35.76mL

7.15mL

3.58mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories